Merck KGaA sees profit after tax soar 51% in the 1st qtr of 2006 after strong Rx sales
German drugmaker and industrial chemicals group Merck KGaA says that its first-quarter 2006 sales rose 16% on the like, year-ago period, to 1.58 billion euros ($1.99 billion), boosted by high earnings from its prescription drugs.
According to the Darmstadt-based group, its operating income jumped 46% to 288.0 million euros due entirely to good business development, as its earnings before interest and tax jumped 37% to 269.0 million euros.
The firm noted that, during the period, the underlying tax rate dropped to 28% from 31% in the year-ago quarter, which helped its profit after tax soar a massive 51%, to 184.0 million euros equivalent to a 50.8% surge in earnings per share to 0.95 euro.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze